Trials / Completed
CompletedNCT05052476
First Line Dose-efficacy Study of Bactecal® D Liquid for Infant Colic
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Astel Medica · Industry
- Sex
- All
- Age
- 2 Weeks – 8 Weeks
- Healthy volunteers
- Not accepted
Summary
This randomized, open label, dose-response study will be realized at the first line with Bactecal® D Liquid. The objective is to investigate Bactecal® D Liquid in the context of infantile colics. The patients will be randomized into two arms, A and B, in function of the intervention dose. The quality of life of te parents as well as the daily median crying time and the number of daily crying will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Bactecal® D Liquid | The patients will be randomized into two arms, A and B, in function of the intervention dose |
Timeline
- Start date
- 2022-04-08
- Primary completion
- 2023-10-08
- Completion
- 2023-10-16
- First posted
- 2021-09-22
- Last updated
- 2023-11-28
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05052476. Inclusion in this directory is not an endorsement.